A carbon-based biosensing platform simultaneously measured contraction and electrophysiology of iPSC-cardiomyocyte monolayers, validating its use for disease modeling and drug testing.
A novel carbon-based biosensing platform enables simultaneous measurement of contraction and electrophysiology in iPSC-cardiomyocyte monolayers for disease modeling and drug testing.
Absolute Event Rate: 0% vs 0%
model of drug-induced cardiac arrhythmia was established to further validate the platform for disease modeling and drug testing.
Dou et al. (Fri,) reported a other. A carbon-based biosensing platform simultaneously measured contraction and electrophysiology of iPSC-cardiomyocyte monolayers, validating its use for disease modeling and drug testing.